Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Dravet syndrome treatment bexicaserin shows promise in trial

Treatment with the experimental oral therapy bexicaserin led to sustained reductions in seizure frequency for children with Dravet syndrome and other types of developmental and epileptic encephalopathies (DEEs), according to new data from the PACIFIC Phase 1/2a clinical trial and its open-label extension study. The findings were announced by…

Fintepla more potent than others in taming Dravet seizures: Study

Among recent treatments to reduce the risk of seizures in people with Dravet syndrome, Fintepla (fenfluramine) appears to be the most potent, according to a new analysis. “In [Dravet syndrome], [Fintepla] provided significantly greater efficacy compared with other [anti-seizure medications], and it was generally well tolerated,” researchers wrote…

Diacomit may be effective for hard-to-treat seizures outside Dravet

Diacomit (stiripentol), known to help control seizures in people with Dravet syndrome, also may aid those with other childhood disorders marked by hard-to-treat seizures, according to a study out of Spain. “Although further prospective studies are needed, our findings suggest that add-on [Diacomit] may be a therapeutic option for…